Boston, Massachusetts, United States The company was established in North America in United States. The leading representative office of defined VC is situated in the Boston.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The increased amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Omega Funds performs on 7 percentage points more the average number of lead investments. Speaking about the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2017.
Besides them, we counted 3 critical employees of this fund in our database.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Intarcia Therapeutics, Gossamer Bio, Beam Therapeutics. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular fund investment industries, there are Biotechnology, Medical.
The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the Omega Funds, startups are often financed by Polaris Partners, Flagship Pioneering, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Abingworth, The Baupost Group. In the next rounds fund is usually obtained by Polaris Partners, Atlas Venture, The Baupost Group.
Related Funds
Funds with similar focus
| Fund Name | Location |
| 3W Partners | Missouri, Saint Louis, United States |
| Aesop Capital | California, San Francisco, United States |
| Assets New Ventures | - |
| Brio Capital Management | New York, New York, United States |
| JNS HOLDINGS | Japan, Tokyo |
| MAN Truck & Bus | Bayern, Germany, Munich |
| Mintian Capital | - |
| Pentech Ventures | City of Edinburgh, Scotland, United Kingdom |
| Platform Investment Partners | Gauteng, Johannesburg, South Africa |
| SAINT-CARE HOLDINGS | Japan, Tokyo |
| Shenshang Xingye Fund | - |
| Shenzhen Qianhai Huaye Yuan Touzi | China, Guangdong, Shenzhen |
| TCG Crossover | California, Palo Alto, United States |
| TrustCapital | India, Maharashtra, Mumbai |
| Ufi Ventures | England, London, United Kingdom |
| Yanlingxian Qianqian Shangmao | China, Henan, Henan |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
XII Medical | $45M | 21 Aug 2024 | Union City, California, United States | ||
Third Arc Bio | $165M | 23 Jul 2024 | Boston, Massachusetts, United States | ||
Scorpion Therapeutics | $150M | 16 Jul 2024 | Boston, Massachusetts, United States | ||
Marea Therapeutics | $190M | 18 Jun 2024 | San Francisco, California, United States | ||
Endeavor BioMedicines | $132M | 24 Apr 2024 | California, United States | ||
Esker Therapeutics | $259M | 06 Mar 2024 | - | ||
ARTBIO | $90M | 07 Dec 2023 | Oslo, Norway | ||
Eyebiotech | $65M | 14 Nov 2023 | New York, New York, United States | ||
ARTBIO | $23M | 21 Jun 2023 | Oslo, Norway |
– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.
– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
XII Medical | $45M | 21 Aug 2024 | Union City, California, United States | ||
Third Arc Bio | $165M | 23 Jul 2024 | Boston, Massachusetts, United States | ||
Scorpion Therapeutics | $150M | 16 Jul 2024 | Boston, Massachusetts, United States | ||
Marea Therapeutics | $190M | 18 Jun 2024 | San Francisco, California, United States | ||
Endeavor BioMedicines | $132M | 24 Apr 2024 | California, United States | ||
Esker Therapeutics | $259M | 06 Mar 2024 | - | ||
ARTBIO | $90M | 07 Dec 2023 | Oslo, Norway | ||
Eyebiotech | $65M | 14 Nov 2023 | New York, New York, United States | ||
ARTBIO | $23M | 21 Jun 2023 | Oslo, Norway |
